Yakult trial takes 4SC's resminostat into NSCLC
This article was originally published in Scrip
Following the news in June that 4SC was cutting around 15% of its staff to reduce costs and focus resources on its lead development project resminostat (scripintelligence.com, 20 June 2013), it must come as some relief to the German biotech firm that the anticancer is now moving forward in a new indication in Japan.
You may also be interested in...
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.
New long-term clinical data with Takeda’s dengue vaccine contender show a durable response against all four serotypes and support the dosing regimen in an ongoing pivotal study.